About Pharmasset (NASDAQ:VRUS)
Pharmasset, Inc. is a clinical-stage pharmaceutical company focused on discovering, developing, and commercializing novel drugs to treat viral infections. The Company focuses on the development of nucleoside/tide analogs as oral therapeutics for the treatment of chronic hepatitis C virus (HCV) infection. Nucleoside/tide analogs are a class of compounds, which act as alternative substrates for the viral polymerase, thus inhibiting viral replication. The Company has three clinical-stage product candidates. It also has a series of preclinical candidates in preparation for clinical development. The three clinical product candidates include RG7128, PSI-7977 and PSI-938. In January 2012, Gilead Sciences, Inc. acquired Pharmasset, Inc.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolNASDAQ:VRUS
CUSIPN/A
WebN/A
Phone+1-609-6134100
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
EmployeesN/A
Outstanding SharesN/A
Pharmasset (NASDAQ:VRUS) Frequently Asked Questions
What is Pharmasset's stock symbol?
Pharmasset trades on the NASDAQ under the ticker symbol "VRUS."
Has Pharmasset been receiving favorable news coverage?
Media stories about VRUS stock have trended positive this week, Accern Sentiment reports. The research firm identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Pharmasset earned a coverage optimism score of 0.41 on Accern's scale. They also assigned media stories about the healthcare company an impact score of 45.77 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.
How do I buy shares of Pharmasset?
Shares of VRUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How can I contact Pharmasset?
Pharmasset's mailing address is 303A College Rd E, PRINCETON, NJ 08540-6608, United States. The healthcare company can be reached via phone at +1-609-6134100.
MarketBeat Community Rating for Pharmasset (VRUS)
MarketBeat's community ratings are surveys of what our community members think about Pharmasset and other stocks. Vote "Outperform" if you believe VRUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VRUS will underperform the S&P 500 over the long term. You may vote once every thirty days.
Pharmasset (NASDAQ:VRUS) Analyst Ratings History
| Date | Brokerage | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
(Data available from 4/26/2016 forward)
Pharmasset (NASDAQ:VRUS) Earnings History and Estimates Chart
Pharmasset (NASDAQ VRUS) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/14/2011 | Q4 2011 | ($0.31) | ($0.33) | | | View | N/A |  |
| 7/25/2011 | | ($0.57) | ($0.60) | | | View | N/A | |
| 4/25/2011 | | $0.65 | ($0.55) | | | View | N/A | |
| 2/7/2011 | Q1 2011 | ($0.28) | ($0.34) | | | View | N/A | |
| 11/23/2010 | Q4 2010 | ($0.23) | ($0.30) | | | View | N/A | |
| 8/9/2010 | Q3 2010 | ($0.26) | ($0.25) | | | View | N/A | |
| 5/5/2010 | Q2 2010 | ($0.23) | ($0.27) | | | View | N/A | |
| 2/9/2010 | Q1 2010 | ($0.22) | ($0.25) | | | View | N/A | |
| 11/25/2009 | Q4 2009 | ($0.27) | ($0.27) | | | View | N/A | |
| 8/10/2009 | Q3 2009 | ($0.20) | ($0.13) | | | View | N/A | |
| 5/11/2009 | Q2 2009 | ($0.25) | ($0.30) | | | View | N/A | |
| 2/9/2009 | Q1 2009 | ($0.26) | ($0.39) | | | View | N/A | |
| 8/14/2008 | Q3 2008 | ($0.31) | ($0.35) | | | View | N/A | |
| 5/15/2008 | Q2 2008 | ($0.22) | ($0.28) | | | View | N/A | |
| 2/14/2008 | Q1 2008 | ($0.28) | ($0.29) | | | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
Pharmasset (NASDAQ:VRUS) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Pharmasset (NASDAQ VRUS) Insider Trading and Institutional Ownership History
Pharmasset (NASDAQ VRUS) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
(Data available from 1/1/2013 forward)
Pharmasset (NASDAQ VRUS) News Headlines
| Source: |
|
No headlines for this company have been tracked by MarketBeat.com
Pharmasset (NASDAQ:VRUS) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Pharmasset (NASDAQ:VRUS) Income Statement, Balance Sheet and Cash Flow Statement
Pharmasset (NASDAQ VRUS) Stock Chart for Thursday, April, 26, 2018
Loading chart…
